GlobeNewswire

BroadSoft Announces New BroadSoft UC-One SaaS Solution

Dela

CBTS is first customer deploying UC-One SaaS new cloud deployment option to offer enterprises quick access to cloud UC benefits

GAITHERSBURG, Md., March 12, 2018 (GLOBE NEWSWIRE) -- BroadSoft, Inc. now a part of Cisco, and a global market leader in cloud calling, meeting, messaging and contact center software as a service (SaaS), has made it quicker and easier than ever for BroadWorks® service providers to provide businesses access to popular BroadSoft cloud unified communications (UC) capabilities by launching UC-One SaaS in North America and EMEA. CBTS, a wholly-owned subsidiary of Cincinnati Bell, is the first service provider to deploy the new UC-One SaaS offer it to its customers.

UC-One SaaS is a new cloud delivery option which allows service providers to add UC-One capabilities in the cloud to their existing BroadWorks call control platform without the need for new software or the complexity of branding clients. Onboarding is simple and intuitive and takes mere minutes, allowing service providers to quickly deliver a comprehensive cloud UC service to end users.

UC-One is an intuitive collaboration application for calling, messaging, and meeting - ideal for companies of all sizes with mobile and dispersed employees. It includes all the essential unified communications and collaboration capabilities including HD voice and video, instant messaging, presence, file sharing, screen sharing, online meeting rooms with guest access, and integration with popular business applications to provide quick access to content during conversations. UC-One improves workplace collaboration, productivity and mobility, and is available on desktop, mobile and tablet.

"We believe hybrid deployment models now available with UC-One will become an increasingly popular solution in the future, as service providers focus on scalability and simple implementation," said Scott Hoffpauir, chief technology officer at BroadSoft. "We are delighted that CBTS is the first to utilize our new cloud unified communications solution."

"Adding a cloud component to our standing unified communications solution was a logical choice for our company given recent company expansion," said Joe Putnick, Vice President and Chief Solution Architect, CBTS. "The BroadSoft SaaS solution will help us implement better communications more widely, with less investment in time and costs, and meet the needs of our enterprise and mid-market customers."

UC-One SaaS is both a technology and marketing accelerator. It also includes an easy-to-brand digital microsite with videos, tutorials and collateral, where end users can sign up for a free 30-day trial of the service.

UC-One SaaS gives service providers a number of other advantages including zero-touch end-user self-activation, real-time branding, continuous agile introduction of new features and software updates, and Powered by BroadSoft go-to-marketing support to help them with their customer buying journey from awareness, onboarding, nurturing and user adoption to selling and ongoing support.

To find out more about UC-One SaaS, click here.

About BroadSoft
BroadSoft, now a part of Cisco, is a technology innovator in cloud PBX, unified communications, team collaboration, and contact center solutions for businesses and service providers across 80 countries. We aim to empower users and teams to share ideas and work simply to achieve breakthrough performance. For additional information, visit www.BroadSoft.com.

Twitter | LinkedIn | BroadSoft Blog

About CBTS

CBTS is a wholly owned subsidiary of Cincinnati Bell (NYSE:CBB) that serves enterprise and midmarket clients in all industries across the United States and Canada. From Unified Communications to Cloud Services and beyond, CBTS combines deep technical expertise with a full suite of flexible technology solutions that drive business outcomes, improve operational efficiency, mitigate risk, and reduce costs for its clients.  For more information, please visit www.cbts.com. The information on the Company's website is not incorporated by reference in this press release.

Investor Relations:

Chris Martin
BroadSoft
+1 561-404-2130
cmartin@broadsoft.com

Media Relations:

Matter for BroadSoft
Erin Knapp
Matter
+1 617-502-6546
BroadSoft@matternow.com 

AxiCom (EMEA)
Tom Johnson
AxiCom
+44 7960 209361
BroadSoft@axicom.com

Navigate Communication (APAC)
Terry Alberstein
+61 (0) 458-484-921
terry@navigatecommunication.com.au 

BroadSoft
Niaobh (Neve) Levestam
BroadSoft
+44 7919 605660
nlevestam@broadsoft.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BroadSoft, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum